83 related articles for article (PubMed ID: 22388160)
21. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Heresco-Levy U; Javitt DC; Ebstein R; Vass A; Lichtenberg P; Bar G; Catinari S; Ermilov M
Biol Psychiatry; 2005 Mar; 57(6):577-85. PubMed ID: 15780844
[TBL] [Abstract][Full Text] [Related]
22. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
[TBL] [Abstract][Full Text] [Related]
23. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
[TBL] [Abstract][Full Text] [Related]
24. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial.
Gattaz WF; Diehl A; Geuppert MS; Hubrich P; Schmitt A; Linde I; Maras A; Dittmann RW
Pharmacopsychiatry; 2004 Nov; 37(6):279-85. PubMed ID: 15551194
[TBL] [Abstract][Full Text] [Related]
26. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
[TBL] [Abstract][Full Text] [Related]
27. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
28. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
29. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
Isitt JJ; Nadipelli VR; Kouassi A; Fava M; Heidbreder C
Schizophr Res; 2016 Jul; 174(1-3):126-131. PubMed ID: 27066860
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
[TBL] [Abstract][Full Text] [Related]
32. Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies.
Ayan-Oshodi M; Wondmagegnehu ET; Lowe SL; Kryzhanovskaya L; Walker DJ; Kinon BJ
J Clin Psychopharmacol; 2012 Jun; 32(3):408-11. PubMed ID: 22544017
[TBL] [Abstract][Full Text] [Related]
33. Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.
Ortega I; Perez-Ruixo JJ; Stuyckens K; Piotrovsky V; Vermeulen A
J Clin Pharmacol; 2010 Mar; 50(3):293-310. PubMed ID: 20056804
[TBL] [Abstract][Full Text] [Related]
34. Olanzapine and haloperidol for residual symptoms.
de Haan L; van Beveren N
Am J Psychiatry; 2005 Jul; 162(7):1392-3; author reply 1393. PubMed ID: 15994737
[No Abstract] [Full Text] [Related]
35. Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia.
Caforio G; Di Giorgio A; Rampino A; Rizzo M; Romano R; Taurisano P; Fazio L; De Simeis G; Ursini G; Blasi G; Nardini M; Mancini M; Bertolino A
J Clin Psychopharmacol; 2013 Dec; 33(6):810-2. PubMed ID: 24113675
[No Abstract] [Full Text] [Related]
36. Methodological concerns in a trial of ziprasidone and olanzapine.
Ross DE
Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
[No Abstract] [Full Text] [Related]
37. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
[TBL] [Abstract][Full Text] [Related]
39. Positive findings for negative symptoms of schizophrenia: no longer untreatable?
Stahl SM
Acta Psychiatr Scand; 2006 Nov; 114(5):301-2. PubMed ID: 17022789
[No Abstract] [Full Text] [Related]
40. Methodological concerns in a trial of ziprasidone and olanzapine.
Carnahan RM; Perry PJ
Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
